Salubris Bio
  • About Us
    • Mission
    • Team
    • Our Focus
      • Pipeline
    • History
  • Research Focus
    • Cardio R&D
      • Heart Failure
      • Neuregulin
      • JK07
      • Clinical Trials
    • Oncology R&D
      • Oncology Overview
      • Focus Areas
    • Neurology R&D
  • Clinical Trials
  • News & Events
  • Careers
  • Contact
Select Page

SalubrisBio parent company Salubris Pharmaceuticals announces $265M investment from the Carlyle Group to further innovative R&D

By: jonadmin|Published on: Oct 27, 2020|Categories: |

Recent Posts

  • Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction
  • Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer
  • Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases

Recent Comments

    Salubris Biotherapeutics, Inc © 2017-2023 | Privacy Policy | Terms & Conditions | site by Pierrot
    Maryland Tech Council | Better Together